全部文献期刊会议图书|学者科研项目
中外文文献  中文文献  外文文献
作者:Xinyuan Wang , Thomas Meul , Silke Meiners
来源:[J].Pharmacology and Therapeutics(IF 7.793), 2020
摘要:Abstract(#br)The proteasome is a well-identified therapeutic target for cancer treatment. It acts as the main protein degradation system in the cell and degrades key mediators of cell growth, survival and function. The term “proteasome” embraces a whole family of distinct co...
作者:Wei Qiang , Fang Sui , Jingjing Ma ...
来源:[J].Endocrine(IF 2.25), 2017, Vol.56 (1), pp.98-108
摘要:Proteasome inhibitors are promising antitumor drugs with preferable cytotoxicity in malignant cells and have exhibited clinical efficiency in several hematologic malignancies. P53-dependent apoptosis has been reported to be a major mechanism underlying. However, apoptosis can als...
作者:Yun-Jin Hwang , Du-Hyong Cho
来源:[J].Biochemical and Biophysical Research Communications(IF 2.406), 2020, Vol.524 (4), pp.853-860
摘要:... In conclusion, we demonstrated that telmisartan inhibits VSMC contractility and vessel contraction by activating AMPK/proteasome/MLCK degradation signaling axis. These results suggest that telmisartan can be used to treat pathological vasospasms.
作者:Barbara A. Zieba , Laurent Henry , Matthieu Lacroix ...
来源:[J].Journal of Dermatological Science(IF 3.52), 2017
摘要:Abstract(#br)Background(#br)The ubiquitin proteasome pathway is involved in the pathogenesis of psoriasis and proteasome subunits are increased in lesional psoriatic skin. Recent works have highlighted that proteasome levels can be regulated through modulation of proteasome assem...
作者:Qi Sun , Tongliang Zhou , Dandan Xi ...
来源:[J].European Journal of Medicinal Chemistry(IF 3.499), 2020, Vol.192
摘要:Abstract(#br)A series of tripeptidic proteasome inhibitors with furylketone as C-terminus were designed and synthesized. Biochemical evaluations against β1, β2 and β5 subunits revealed that they acted selectively on β5 subunit with IC 50 s against chymotrypsin-like (CT-L)...
作者:Catarina Sofia Henriques de Jesus , Ana Maria Chiorcea-Paquim , Madalina Maria Barsan ...
来源:[J].Talanta(IF 3.498), 2019, Vol.199, pp.32-39
摘要:Abstract(#br)The majority of eukaryotic regulated protein turnover is performed by the proteasome, a multi-catalytic enzyme. Due to the fact that proteasome enzyme abnormal functioning was observed in different malignant cells, the proteasome is becoming a target for medical trea...
作者:Rishi K. Devulapalli , Jacob L. Nelsen , Sabrina A. Orsi ...
来源:[J].Neuroscience(IF 3.122), 2019, Vol.418, pp.1-14
摘要:Abstract(#br)The ubiquitin-proteasome system (UPS) controls the degradation of ~ 90% of short-lived proteins in cells and is involved in activity- and learning-dependent synaptic plasticity in the brain. Calcium/calmodulin dependent protein kinase II (CaMKII) and Protein Kinase A...
作者:Md Tanvir Islam , Teru Ogura , Masatoshi Esaki
来源:[J].Biochemical and Biophysical Research Communications(IF 2.406), 2020, Vol.523 (4), pp.835-840
摘要:Abstract(#br)The 26S proteasome is the major degradation machinery for soluble proteins in eukaryotes. Recent evidence reveals the existence of an alternative ATP-powered protein degradation complex, the Cdc48-20S proteasome complex, and we have identified yeast Sod1, a copper-zi...
作者:Muthukumar Elangovan , Hae Kwan Chong , Jin Hee Park ...
来源:[J].Journal of Cell Communication and Signaling, 2017, Vol.11 (3), pp.265-273
摘要:... Moreover, we noticed that phosphorylated Ube2j1 is rapidly degraded by the proteasome during ER stress cell recovery. Taken together, these data suggest that Ube2j1 and its phosphorylation is important for transient ER stress cell recovery and the phosphorylated Ube2j1 is deg...
作者:Makoto Tanaka , Yunhao Zhu , Masafumi Shionyu ...
来源:[J].European Journal of Medicinal Chemistry(IF 3.499), 2018, Vol.146, pp.636-650
摘要:Abstract(#br)Ridaifen-F (RID-F) potently inhibits proteolytic activities of the 20S proteasome but poorly inhibits those of the 26S proteasome. Here, we report preparation of several conjugates in which various peptides are connected to RID-F. Conjugates with peptides consisti...

我们正在为您处理中,这可能需要一些时间,请稍等。

资源合作:cnki.scholar@cnki.net, +86-10-82896619   意见反馈:scholar@cnki.net

×